DMI Clinical Commentary:
Marketing, Not Science

Independent analyses, including the 2026 Pediatric Physical Therapy paper, describe DMI as a commercial rebranding and refinement of CME, not a fundamentally new modality. The founders themselves stated in 2022 that one of the “huge reasons” they moved from CME to DMI was the lack of research on CME.

Changing the name, adding a structured curriculum, and updating the marketing language to include “neuroplasticity,” “task-specific,” and “motor learning” does not create a new evidence base. The core techniques — therapist-driven facilitation of postural responses, proximal-to-distal holds, cephalocaudal progression — remain recognisably related to the older approach. Self-declaration of distinctiveness by the commercial owners is not scientific differentiation.

These are legitimate, well-established principles that apply to any active, intensive, varied motor experience in young children. Citing Kleim, Edelman, or Novak does not validate DMI any more than it validates walking practice, goal-directed training, or constraint-induced movement therapy.

The commentary never demonstrates that the specific handling techniques of DMI produce superior or even measurable neuroplastic change compared with other intensive approaches. It simply lists general neuroscience principles and asserts that DMI “follows” them. This is classic pseudoscientific scaffolding: borrow real science, attach it to an untested product, and claim legitimacy by association.

“Automatic postural responses” language belongs to older hierarchical and reflex-based models. Modern motor learning science emphasises child-initiated, goal-directed, task-specific practice in functional contexts — not therapist-provoked reactions.

The commentary claims task-specificity while describing exercises that are largely therapist-driven and decontextualised. There is no published evidence that DMI produces better postural control outcomes than existing approaches that actually measure and prioritise functional goal attainment. The assertion remains untested marketing.

The importance of early, active intervention in cerebral palsy is not in dispute. High-quality evidence supports early diagnosis and early motor interventions that emphasise active exploration and task practice. That evidence does not extend to DMI.

Using the well-documented benefits of early intervention as a justification for an unproven method is a bait-and-switch. The commentary correctly notes that motor potential stabilises and secondary musculoskeletal complications increase without timely intervention. It then leaps, without data, to the conclusion that DMI is therefore the appropriate vehicle. Correlation is not endorsement.

Movement of any kind that involves weight-bearing, stretching, and head movement provides sensory input and can influence BDNF. This is not unique to DMI. The commentary presents general physiological effects of exercise as if they were specific mechanistic evidence for their branded protocol.

There are no published studies measuring BDNF, synaptic density, or any other neurophysiological marker in children receiving DMI versus controls. The mechanism claims are speculative and untested.

Dynamic stretching and progressive loading can be useful. Again, this is not proprietary. Many evidence-based programmes incorporate progressive loading and range-of-motion work within functional goals.

The commentary offers no comparative data showing that DMI produces superior alignment or reduced contracture rates compared with standard early active intervention plus orthopaedic surveillance. Anecdotal claims of “improved alignment” without controlled measurement or long-term radiographic or clinical outcome data are worthless.

This is the purest form of selection and expectancy bias. Families who pay large sums for intensives and therapists who have invested in expensive certification are highly motivated to perceive and report progress. Natural developmental change, concurrent therapies, increased total therapy dose, and placebo effects are uncontrolled.

Mentioning that standardised tools “are used” is not the same as publishing independently analysed, aggregated data with appropriate controls and follow-up. Five years after commercial launch, no such data exist in the peer-reviewed literature. Anecdote remains the primary evidence.

This is the most revealing admission in the entire document. DMI has been commercially available and actively marketed since 2021. Thousands of therapists have been trained across dozens of countries. Families have paid for intensives. Yet the founders still describe the research as “emerging” or “in planning.”

In legitimate clinical science, the evidence precedes widespread commercial rollout. Here the product was sold first and the research promised later. That sequence is the hallmark of marketing, not science. A single confounded conference abstract on two SMA infants post-gene therapy remains the only published empirical data point. That is Sackett Level 5 — no evidence.

A well-organised training programme and attention to therapist ergonomics are good commercial practices. They are not evidence of clinical efficacy. Many unproven or disproven interventions have had elaborate certification pathways.

Structured education does not convert an untested method into an evidence-based one. Safety protocols are the minimum ethical requirement; they do not prove the intervention works.

A genuine clinical commentary is written by independent experts, published in a peer-reviewed journal, and critically evaluates both supporting and contradictory evidence. This document is self-published on the commercial website of the product’s owners.

It selectively cites general neuroscience and early-intervention literature while ignoring the complete absence of DMI-specific experimental evidence. It responds to legitimate scientific criticism by restating marketing claims rather than producing data. That is not clarification of scientific basis. It is brand defence.